US3865108A - Expandable drug delivery device - Google Patents
Expandable drug delivery device Download PDFInfo
- Publication number
- US3865108A US3865108A US377350A US37735073A US3865108A US 3865108 A US3865108 A US 3865108A US 377350 A US377350 A US 377350A US 37735073 A US37735073 A US 37735073A US 3865108 A US3865108 A US 3865108A
- Authority
- US
- United States
- Prior art keywords
- base
- medicament
- capillary
- containing zone
- body cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
Definitions
- a drug delivery device having a drug containing zone 330, 333, 314, 315, 270, 271, 285; 222/92, associated with and partially defined by a material 95, 206, 103, 105 which swells on contact with body fluids. When swelling occurs, the pressure on the drug containing zone (56] References Cited expels the drug from the device.
- the device of this invention comprises a generally cylindrical or prismatic base incorporating a substance which swells upon contact with natural body fluids.
- the base of the device either defines a hollow core containing a medicament or has disposed in a relatively restrained position around or adjacent its outer surface a medicament containing tube or sheath.
- the base at least partially defines a medicament containing zone of restricted dimensions.
- the medicament is dispensed into the body cavity due to the pressure generated on the medicament containing zone by virtue of the swelling of the base.
- FIG. 1 is a longitudinal cross-section of a device of this invention
- FIG. 2 is a vertical cross-section of the device of FIG. 1 taken along lines 22;
- FIG. 3 is a longitudinal cross-section of the device of FIGS. 1 and 2 after use;
- FIG. 4 is a vertical cross-section of the used device of FIG. 3 taken along lines 4--4;
- FIG. 5 is a longitudinal cross-section of another de vice of this invention.
- FIG. 6 is a vertical cross-section of the device of FIG. 5 taken along lines 6-6;
- FIG. 7 is a vertical cross-section of still another device of this invention illustrating the same both before and after exposure;
- FIG. 8 also is a vertical cross-section of another device of this invention illustrating the same both before and after exposure;
- FIG. 9 is a vertical cross-section of yet another device of this invention illustrating the same both before and after exposure;
- FIG. 10 is a view in perspective of still another device of this invention.
- FIG. 11 is a cross-section of the device of FIG. 10 taken along lines Ill-I1;
- FIG. 12 is a vertical cross-section of another device of this invention.
- FIG. 13 is a top view of another device of this invention.
- FIG. 14 is a top view of yet another device of this invention.
- FIGS. 1 through 11 illustrate embodiments of the invention wherein the base of the device defines a hollow medicament filled core.
- the device of FIGS. 1 and 2 consists of a base, 1, formed of a material which will expand multi-directionally upon contact with body fluids, the base defining a hollow core, 2.
- the hollow core, 2, contains a medicament. 3, which is encased in a col- 2 lapsible tube, 4, having a closed end, 5,,projecting outward from the end, 6, of the base, I.
- the end of the collapsible tube is severed and the device inserted into a body cavity such as the cervix.
- the base, 1, will expand multi-directionally upon contact with body fluid and the resistance to expansion offered by the cervix causes the tube to collapse andthe medicament to be dispensed into the body cavity.
- the cervical canal is gradually enlarged to accommodate thev increased dimensions.
- FIGS. 3 and 4 illustrate the device of FIGS. I and 2 after use.
- the capillary tube, 4 has been compressed and its contents have been expelled into the uterine cavity.
- the device may be of any shape, it is preferred that it be prismatic or cylindrical for enhancing comfort and facilitating insertion.
- the device also preferably has a tail, 7, to assist in its removal after use. It may also be advantageous to mold the base of the device with an enlarged end portion, 8, to prevent the device from accidentally being inserted completely into the uterus. It is not practical to give a particular dimension for the device since the size employed will depend upon whether the device is used in the nostrils, vagina, for treating rectal disorders, etc.
- the base of the device is made either primarily of a material which will itself expand upon contact with body fluids, or is made of an expandable material having incorporated therein a substance which will expand upon contact with body fluids.
- expandable material is meant a material which will swell or expand beyond its original or normal limits.
- Such expandable materials include brown algae, in particular species of the genus Laminaria; polysaccharides derived from brown and red seaweeds, such as alkali metal and ammonium salts of alginic acids and carrageenan; biosynthetic polysaccharides such as xanthan gum; natural gums, such as guar gum, karaya, tragacanth, psyllium seed, and locust bean; cellulose derivatives such as microcrystallinecellulose; synthetic resins derived from cellulose, such as carboxymethylcellulose, and nonionic cellulose gums such as methylcellulose and hydroxypropyl cellulose; synthetic water-absorbing polymers such as polyvinyl alcohol, polyacrylamide, polyvinylpyrrolidone, and ethylene oxide polymers; and modified starches such as pre-gelatinized corn starch.
- Preferred among the expandable materials are those derived from brown algae and in particular those derived from species of the genus Laminaria.
- the capillary tube may be constructed of any thin, easily collapsible metal or plastic material such as aluminum or Teflon.
- the material must have sufficient strength to protect the medicament during storage prior to use, but at the time of use must be eas- -ily severable and collapsible.
- the hollow core preferably have an oval cross-section to facilitate collapse under pressure; however, any convenient shape may be utilized.
- the base may be desirable to encase the base in an outer skin of highly flexible water-permeable material, 9a, such as is illustrated in FIGS. 5 and 6.
- a skin assures that the device will not break apart upon softening and swelling when in contact with body fluids. It may be advantageous to form such a skin ofa material having a high modulus of elasticity so as to exert added pressure on the medicament containing zone as the base attempts to expand.
- Irregular collapse can be avoided by molding a longitudinal 'rib, b, inside the tube as shown in FIG. 7.
- the rib will allow passage of a medicament on either side of it after the tube has collapsed. This may also be accomplished by disposing ribs, 100, at each side of the tube as shown in FIG. 8.
- Irregular collapse may also be overcome by providing a tube with a rectangular cross-section of appropriate stiffness so that the short side walls, 11d, tend to resist collapse and thus permit passage of the drug through the spaces adjacent them as illustrated in FIG. 9.
- the device is preferably cylindrical or prismatic, this does not mean that the base must be formed of only one such solid.
- the base may be of any shape as long as it has smooth sides and corners, and defines a hollow core into which the medicament or a capillary containing the medicament may be inserted.
- the device of FIG. 10 consists of a series of four rods, 101, of a material which swells when in contact with body fluids, arranged in a bundle so as to leave an open core, 102, sufficient to hold a small capillary, 104, containing the active drug, 103.
- the rods may be kept in their illustrated configuration by an outer water-permeable covering, 109, such as the type previously described. The expansion of the rods will fill the void occupied by the capillary and thus extrude the contents into the body cavity.
- a particularly adaptable substance for a device of this design is the stalk of the seaweed of the Laminaria family which, when dried, becomes rigid and bone-like. When exposed to water, the stalk will increase in diameter nearly three-fold and become soft and flexible.
- FIGS. 12 through 14 illustrate embodiments of the invention wherein the base of the device has a medicament containing tube or sheath disposed in a relatively restrained position around or adjacent its outer surface.
- the base, 201, of the device illustrated constitutes a solid core surrounded by medicament, 203, encased in a sheath,.209.
- the sheath is not permeable to fluids but the base absorbs body fluids through its ends thus causing the desired effect.
- the medicament containing tube, 304, of the device illustrated therein is helically wound around the base, 301, and anchored by passing it through the base at either end, 310. As the base expands, medicament is delivered through one of the ends, 310.
- the medicament containing tube, 404, of the device illustrated therein is secured adjacent to the surface of the base, 401, by pass ing the same through the base at either end, 410. As the base expands, medicament is delivered through one of the ends, 410.
- a device for the delivery of a medicament to a body cavity comprising a base, said base at least partially defining a medicament containing zone of restricted dimensions, said base being expandable and incorporating a material which expands sufficiently upon contact with body fluids to expand said base, said material being selected from the group consisting of brown algae, polysaccharides derived from brown and red seaweeds, biosynthetic polysaccharides, natural gums, cellulose derivatives, synthetic resins derived from cellulose, polyacrylamide, polyvinylpyrrolidone, ethylene oxide polymers, and modified starches, and said medicament containing zone being disposed in pressure responsive relation to said expandable base such that upon insertion of the device into a body cavity pressure is exerted on the medicament containing zone as a result of resistance to expansion by the base within the body cavity which causes the base to compress the medicament containing zone resulting in the medicament contained therein being dispensed into the body cavity.
- a collapsible capillary tube containing said medicament is disposed in fixed position adjacent the surface of said base and the peripheral surface of said tube defining an annular medicament containing zone.
Abstract
A drug delivery device having a drug containing zone associated with and partially defined by a material which swells on contact with body fluids. When swelling occurs, the pressure on the drug containing zone expels the drug from the device.
Description
111111661 @tates Fatent 1 1 [111 gamma Marion 1 Feb. 11, 1975 1 1 EXPANDABLE DRUG DIEUVERY DEVICE 2.6431027 6/1953 2.687.729 8/1965 [75] Inventor: William L. Hartop, Bernardsvtlle, 2959250 H960 NJ. 3,102.540 9/1963 3.202.324 8/1965 [73] Assignee. ggliitgrlllhrjrjnaceutical Corporation, 3'490454 H1970 3.559.646 2/1971 [22] Filed: July 9, 1973 3,760,805 973 3.760.984 9/1973 Theeuwes 128/260 X [21] Appl. No.: 377,350
Related Application Data Primary Examiner-Richard A. Gaudet [63] Continuation-impart of Ser. No. 144,174, May 17. Assistant Examiner-J. C. McGowan 1971. flbandoned- Attorney, Agent, or Firm-Benjamin F. Lambert 152] 11.5. C1 128/260, 128/270, 222/95 [51] int. CI A6111 31/00 [57 ABSTRACT [511] Field of Search 128/260, 127, 130. 268,
128/215, 216, 253, 213, 2 W, 2 R, 1 R, 329, A drug delivery device having a drug containing zone 330, 333, 314, 315, 270, 271, 285; 222/92, associated with and partially defined by a material 95, 206, 103, 105 which swells on contact with body fluids. When swelling occurs, the pressure on the drug containing zone (56] References Cited expels the drug from the device.
UNlTED STATES PATENTS 10 Cl 14 D F 706,778 8/1902 Pond 128/270 rawmg gums PATENIED FEB] 1 I975 SHEET 10F 2 INVENTOR Maw/n4. hM/QTOP BY mm, (1 Mg ATTORNEY I EXPANDABILE DRUG DELIVERY DEVICE This is a continuation-in-part of co-pending application Ser. No. 144,174 filed May 17,-1971, now abandoned.
Current methods of introducing medicaments such as prostaglandins, for example, into the uterine cavity for the purpose of abortion and the like require the use of in-dwelling catheters and the continual attention of medical personnel to deliver the drug by use of a syringe or by hydrostatic pressure from an outside reservoir. The device of this invention obviates the need for an indwelling catheter and, more. importantly, eliminates the need for an operator to monitor the administration of the drug.
The device of this invention comprises a generally cylindrical or prismatic base incorporating a substance which swells upon contact with natural body fluids. The base of the device either defines a hollow core containing a medicament or has disposed in a relatively restrained position around or adjacent its outer surface a medicament containing tube or sheath. In other words, the base at least partially defines a medicament containing zone of restricted dimensions. In either case, the medicament is dispensed into the body cavity due to the pressure generated on the medicament containing zone by virtue of the swelling of the base.
The invention may be better understood by reference to the attached drawings, wherein FIG. 1 is a longitudinal cross-section of a device of this invention;
FIG. 2 is a vertical cross-section of the device of FIG. 1 taken along lines 22;
FIG. 3 is a longitudinal cross-section of the device of FIGS. 1 and 2 after use;
FIG. 4 is a vertical cross-section of the used device of FIG. 3 taken along lines 4--4;
FIG. 5 is a longitudinal cross-section of another de vice of this invention;
FIG. 6 is a vertical cross-section of the device of FIG. 5 taken along lines 6-6;
FIG. 7 is a vertical cross-section of still another device of this invention illustrating the same both before and after exposure;
FIG. 8 also is a vertical cross-section of another device of this invention illustrating the same both before and after exposure;
FIG. 9 is a vertical cross-section of yet another device of this invention illustrating the same both before and after exposure;
FIG. 10 is a view in perspective of still another device of this invention;
FIG. 11 is a cross-section of the device of FIG. 10 taken along lines Ill-I1;
FIG. 12 is a vertical cross-section of another device of this invention;
FIG. 13 is a top view of another device of this invention;
FIG. 14 is a top view of yet another device of this invention.
FIGS. 1 through 11 illustrate embodiments of the invention wherein the base of the device defines a hollow medicament filled core. The device of FIGS. 1 and 2 consists ofa base, 1, formed of a material which will expand multi-directionally upon contact with body fluids, the base defining a hollow core, 2. The hollow core, 2, contains a medicament. 3, which is encased in a col- 2 lapsible tube, 4, having a closed end, 5,,projecting outward from the end, 6, of the base, I. When in use, the end of the collapsible tube is severed and the device inserted into a body cavity such as the cervix. The base, 1, will expand multi-directionally upon contact with body fluid and the resistance to expansion offered by the cervix causes the tube to collapse andthe medicament to be dispensed into the body cavity. The cervical canal is gradually enlarged to accommodate thev increased dimensions. Thus, when used to dispense a medicament for the termination of pregnancy, for example, the dilation of the cervix will facilitate the abortion.
FIGS. 3 and 4 illustrate the device of FIGS. I and 2 after use. In FIGS. 3 and 4, the capillary tube, 4, has been compressed and its contents have been expelled into the uterine cavity.
While the device may be of any shape, it is preferred that it be prismatic or cylindrical for enhancing comfort and facilitating insertion. The device also preferably has a tail, 7, to assist in its removal after use. It may also be advantageous to mold the base of the device with an enlarged end portion, 8, to prevent the device from accidentally being inserted completely into the uterus. It is not practical to give a particular dimension for the device since the size employed will depend upon whether the device is used in the nostrils, vagina, for treating rectal disorders, etc.
The base of the device is made either primarily of a material which will itself expand upon contact with body fluids, or is made of an expandable material having incorporated therein a substance which will expand upon contact with body fluids. By expandable material is meant a material which will swell or expand beyond its original or normal limits. Examples of such expandable materials include brown algae, in particular species of the genus Laminaria; polysaccharides derived from brown and red seaweeds, such as alkali metal and ammonium salts of alginic acids and carrageenan; biosynthetic polysaccharides such as xanthan gum; natural gums, such as guar gum, karaya, tragacanth, psyllium seed, and locust bean; cellulose derivatives such as microcrystallinecellulose; synthetic resins derived from cellulose, such as carboxymethylcellulose, and nonionic cellulose gums such as methylcellulose and hydroxypropyl cellulose; synthetic water-absorbing polymers such as polyvinyl alcohol, polyacrylamide, polyvinylpyrrolidone, and ethylene oxide polymers; and modified starches such as pre-gelatinized corn starch. Preferred among the expandable materials are those derived from brown algae and in particular those derived from species of the genus Laminaria.
In practice, the capillary tube may be constructed of any thin, easily collapsible metal or plastic material such as aluminum or Teflon. The material must have sufficient strength to protect the medicament during storage prior to use, but at the time of use must be eas- -ily severable and collapsible. The collapsible tube, and
the hollow core, preferably have an oval cross-section to facilitate collapse under pressure; however, any convenient shape may be utilized.
In some cases, it may be desirable to encase the base in an outer skin of highly flexible water-permeable material, 9a, such as is illustrated in FIGS. 5 and 6. Such a skin assures that the device will not break apart upon softening and swelling when in contact with body fluids. It may be advantageous to form such a skin ofa material having a high modulus of elasticity so as to exert added pressure on the medicament containing zone as the base attempts to expand.
It is possible to further improve the operation of the device by modifying the collapsible tube to prevent entrapment of the drug-due to irregular collapse of segments of the tube. Irregular collapse can be avoided by molding a longitudinal 'rib, b, inside the tube as shown in FIG. 7. Thus, the rib will allow passage of a medicament on either side of it after the tube has collapsed. This may also be accomplished by disposing ribs, 100, at each side of the tube as shown in FIG. 8. Irregular collapse may also be overcome by providing a tube with a rectangular cross-section of appropriate stiffness so that the short side walls, 11d, tend to resist collapse and thus permit passage of the drug through the spaces adjacent them as illustrated in FIG. 9.
While it was indicated at the outset that the device is preferably cylindrical or prismatic, this does not mean that the base must be formed of only one such solid. As illustrated in FIG. 10, the base may be of any shape as long as it has smooth sides and corners, and defines a hollow core into which the medicament or a capillary containing the medicament may be inserted. The device of FIG. 10 consists of a series of four rods, 101, of a material which swells when in contact with body fluids, arranged in a bundle so as to leave an open core, 102, sufficient to hold a small capillary, 104, containing the active drug, 103. The rods may be kept in their illustrated configuration by an outer water-permeable covering, 109, such as the type previously described. The expansion of the rods will fill the void occupied by the capillary and thus extrude the contents into the body cavity.
A particularly adaptable substance for a device of this design is the stalk of the seaweed of the Laminaria family which, when dried, becomes rigid and bone-like. When exposed to water, the stalk will increase in diameter nearly three-fold and become soft and flexible.
As an example of the device illustrated in FIGS. 10 and ll, and the manner in which it functions, four rods of Laminaria, each about 2V2 inches long and about A; of an inch in diameter are bound firmly together by means of fine copper wire. A catheter having an inside diameter of 0.025 inches and an outside diameter of 0.047 inches is inserted longitudinally through the space between the rods, is filled with a vegetable dye solution and one end is clamped off. When the device is immersed in water, within 12 minutes the dye solution can be observed issuing from the open end of the catheter. The dye continues to be expelled very slowly at what appears to be a uniform rate for a total of one hour and minutes. Calculations indicate that the rate of expulsion of the dye cannot have exceeded 1 X l0 ml. per minute. This rate conforms to the concept of the delivery of very small doses of highly active medicaments in a continuous fashion.
FIGS. 12 through 14 illustrate embodiments of the invention wherein the base of the device has a medicament containing tube or sheath disposed in a relatively restrained position around or adjacent its outer surface. Referring specifically to FIG. 12, the base, 201, of the device illustrated constitutes a solid core surrounded by medicament, 203, encased in a sheath,.209. The sheath is not permeable to fluids but the base absorbs body fluids through its ends thus causing the desired effect.
Referring to FIG. 13, the medicament containing tube, 304, of the device illustrated therein is helically wound around the base, 301, and anchored by passing it through the base at either end, 310. As the base expands, medicament is delivered through one of the ends, 310.
Finally, referring to FIG. 14, the medicament containing tube, 404, of the device illustrated therein is secured adjacent to the surface of the base, 401, by pass ing the same through the base at either end, 410. As the base expands, medicament is delivered through one of the ends, 410.
What is claimed is:
l. A device for the delivery of a medicament to a body cavity comprising a base, said base at least partially defining a medicament containing zone of restricted dimensions, said base being expandable and incorporating a material which expands sufficiently upon contact with body fluids to expand said base, said material being selected from the group consisting of brown algae, polysaccharides derived from brown and red seaweeds, biosynthetic polysaccharides, natural gums, cellulose derivatives, synthetic resins derived from cellulose, polyacrylamide, polyvinylpyrrolidone, ethylene oxide polymers, and modified starches, and said medicament containing zone being disposed in pressure responsive relation to said expandable base such that upon insertion of the device into a body cavity pressure is exerted on the medicament containing zone as a result of resistance to expansion by the base within the body cavity which causes the base to compress the medicament containing zone resulting in the medicament contained therein being dispensed into the body cavity.
2. The device of claim 1 wherein said base is comprised of a polymeric material and defines a hollow core which constitutes said medicament containing zone. I,
3. The device of claim 1 wherein said expandable material is Laminaria.
4. The device of claim 2 wherein said core contains a collapsible capillary tube containing said medicament.
5. The device of claim 4 in which said capillary is of oval cross-section.
6. The device of claim 1 in which a collapsible capillary tube containing said medicament is disposed in fixed position adjacent the surface of said base and the peripheral surface of said tube defining an annular medicament containing zone.
7. The device of claim 4 in which said capillary contains an inner rib along substantially its entire length.
8. The device of claim 4 in which the capillary contains a plurality of inner ribs along substantially its entire length.
9. The device of claim 4 in which the capillary tube is of rectangular cross-section.
10. The device of claim 6 in which said capillary contains an inner rib along substantially its entire length.
Claims (10)
1. A device for the delivery of a medicament to a body cavity comprising a base, said base at least paRtially defining a medicament containing zone of restricted dimensions, said base being expandable and incorporating a material which expands sufficiently upon contact with body fluids to expand said base, said material being selected from the group consisting of brown algae, polysaccharides derived from brown and red seaweeds, biosynthetic polysaccharides, natural gums, cellulose derivatives, synthetic resins derived from cellulose, polyacrylamide, polyvinylpyrrolidone, ethylene oxide polymers, and modified starches, and said medicament containing zone being disposed in pressure responsive relation to said expandable base such that upon insertion of the device into a body cavity pressure is exerted on the medicament containing zone as a result of resistance to expansion by the base within the body cavity which causes the base to compress the medicament containing zone resulting in the medicament contained therein being dispensed into the body cavity.
2. The device of claim 1 wherein said base is comprised of a polymeric material and defines a hollow core which constitutes said medicament containing zone.
3. The device of claim 1 wherein said expandable material is Laminaria.
4. The device of claim 2 wherein said core contains a collapsible capillary tube containing said medicament.
5. The device of claim 4 in which said capillary is of oval cross-section.
6. The device of claim 1 in which a collapsible capillary tube containing said medicament is disposed in fixed position adjacent the surface of said base and the peripheral surface of said tube defining an annular medicament containing zone.
7. The device of claim 4 in which said capillary contains an inner rib along substantially its entire length.
8. The device of claim 4 in which the capillary contains a plurality of inner ribs along substantially its entire length.
9. The device of claim 4 in which the capillary tube is of rectangular cross-section.
10. The device of claim 6 in which said capillary contains an inner rib along substantially its entire length.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US377350A US3865108A (en) | 1971-05-17 | 1973-07-09 | Expandable drug delivery device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14417471A | 1971-05-17 | 1971-05-17 | |
US377350A US3865108A (en) | 1971-05-17 | 1973-07-09 | Expandable drug delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
US3865108A true US3865108A (en) | 1975-02-11 |
Family
ID=26841747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US377350A Expired - Lifetime US3865108A (en) | 1971-05-17 | 1973-07-09 | Expandable drug delivery device |
Country Status (1)
Country | Link |
---|---|
US (1) | US3865108A (en) |
Cited By (221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3946734A (en) * | 1975-02-19 | 1976-03-30 | The United States Of America As Represented By The Secretary Of State | Apparatus for controlling the release of a drug |
US4005699A (en) * | 1974-10-09 | 1977-02-01 | Louis Bucalo | Methods and apparatus for use in magnetic treatment of the body |
US4041948A (en) * | 1976-07-26 | 1977-08-16 | Johnson & Johnson | Digital tampon |
US4185618A (en) * | 1976-01-05 | 1980-01-29 | Population Research, Inc. | Promotion of fibrous tissue growth in fallopian tubes for female sterilization |
US4192308A (en) * | 1977-10-25 | 1980-03-11 | Alza Corporation | Device using prestretched polymer for dispensing medication |
US4203440A (en) * | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
US4207893A (en) * | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
US4237893A (en) * | 1979-11-28 | 1980-12-09 | Alza Corporation | Cervical dilator |
US4299222A (en) * | 1980-01-08 | 1981-11-10 | Alza Corporation | Self-contained suction pump |
US4304232A (en) * | 1979-03-14 | 1981-12-08 | Alza Corporation | Unit system having multiplicity of means for dispensing useful agent |
US4350271A (en) * | 1980-08-22 | 1982-09-21 | Alza Corporation | Water absorbing fluid dispenser |
US4360013A (en) * | 1980-04-21 | 1982-11-23 | Minnesota Mining And Manufacturing Company | Polymeric acid contraceptive devices |
US4367741A (en) * | 1980-12-22 | 1983-01-11 | Alza Corporation | Dispenser powered by cross-linked hydrophilic polymer grafted to hydrophilic polymer |
WO1984000494A1 (en) * | 1982-07-26 | 1984-02-16 | Health Prod Res | Dilatation device for the cervix |
US4455144A (en) * | 1980-12-04 | 1984-06-19 | Alza Corporation | Dispenser constructed with semipermeable polymer-hydrophilic polymer wall |
FR2561628A1 (en) * | 1984-03-21 | 1985-09-27 | Alza Corp | DEVICE FOR DELIVERING SUBSTANCES WITH SEVERAL COMPONENTS OPERATING IN INTEGRATED UNIT SYSTEM |
EP0168507A1 (en) * | 1981-04-27 | 1986-01-22 | Repromed, Inc. | Osmotic cervical dilator |
US4663148A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising telescopically engaging members |
US4663149A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising inner and outer walls functioning as cooperative unit |
US4692326A (en) * | 1984-03-21 | 1987-09-08 | Alza Corporation | Dispenser comprising inner positioned soft or hard capsule |
US4716031A (en) * | 1984-03-21 | 1987-12-29 | Alza Corporation | Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug |
DE3634864A1 (en) * | 1983-11-02 | 1988-04-14 | Alza Corp | DELIVERY DEVICE FOR RELEASING A TEMPERATURE-RELEVANT MEASURE |
US4764380A (en) * | 1982-03-22 | 1988-08-16 | Alza Corporation | Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills |
US4778607A (en) * | 1984-04-30 | 1988-10-18 | Marathon Oil Company | Method of diluting a concentrated polymer solution for use in a hydrocarbon recovery process |
US4800056A (en) * | 1984-03-21 | 1989-01-24 | Alza Corporation | Process for making dispenser with cooperating elements |
US4814180A (en) * | 1984-03-21 | 1989-03-21 | Alza Corporation | Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container |
US4846279A (en) * | 1988-01-13 | 1989-07-11 | Marathon Oil Company | Method and means for introducing treatment fluid into a well bore |
US4851232A (en) * | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US4855141A (en) * | 1988-03-25 | 1989-08-08 | Alza Corporation | Device comprising means for protecting and dispensing fluid sensitive medicament |
US4871542A (en) * | 1987-04-30 | 1989-10-03 | Ferring Service Center, N.V. | Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract |
US4931285A (en) * | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US4959218A (en) * | 1988-03-25 | 1990-09-25 | Alza Corporation | Method for delivering somatotropin to an animal |
US4976966A (en) * | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
US4996060A (en) * | 1988-03-25 | 1991-02-26 | Alza Corporation | Device comprising liner for protecting fluid sensitive medicament |
US5006346A (en) * | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US5019397A (en) * | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
US5024663A (en) * | 1990-02-21 | 1991-06-18 | Alza Corporation | Self-contained suction pump |
US5024842A (en) * | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
US5035897A (en) * | 1989-09-05 | 1991-07-30 | Alza Corporation | Dosage form for delivering soluble or insoluble drugs |
US5037420A (en) * | 1988-12-13 | 1991-08-06 | Alza Corporation | Delivery system comprising two sections for delivering somatotropin |
US5057318A (en) * | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
US5059423A (en) * | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
US5110596A (en) * | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
US5126142A (en) * | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5135523A (en) * | 1988-12-13 | 1992-08-04 | Alza Corporation | Delivery system for administering agent to ruminants and swine |
US5137727A (en) * | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US5174999A (en) * | 1988-12-13 | 1992-12-29 | Alza Corporation | Delivery system comprising fluid ingress and drug egress |
US5180591A (en) * | 1990-07-11 | 1993-01-19 | Alza Corporation | Delivery device with a protective sleeve |
US5198229A (en) * | 1991-06-05 | 1993-03-30 | Alza Corporation | Self-retaining gastrointestinal delivery device |
US5223265A (en) * | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5234693A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234692A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234694A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Method for increasing feed efficiency in animals |
US5236689A (en) * | 1987-06-25 | 1993-08-17 | Alza Corporation | Multi-unit delivery system |
US5238687A (en) * | 1990-07-11 | 1993-08-24 | Alza Corporation | Delivery device with a protective sleeve |
US5240713A (en) * | 1991-09-27 | 1993-08-31 | Alza Corporation | Dual rate agent delivery device |
US5273752A (en) * | 1989-07-18 | 1993-12-28 | Alza Corporation | Controlled release dispenser comprising beneficial agent |
US5282785A (en) * | 1990-06-15 | 1994-02-01 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
US5340590A (en) * | 1987-06-25 | 1994-08-23 | Alza Corporation | Delivery system with bilayer osmotic engine |
US5391381A (en) * | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5458568A (en) * | 1991-05-24 | 1995-10-17 | Cortrak Medical, Inc. | Porous balloon for selective dilatation and drug delivery |
US5474785A (en) * | 1990-01-24 | 1995-12-12 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
US5498238A (en) * | 1990-06-15 | 1996-03-12 | Cortrak Medical, Inc. | Simultaneous angioplasty and phoretic drug delivery |
US5498255A (en) * | 1993-08-17 | 1996-03-12 | Alza Corporation | Osmotic device for protracted pulsatile delivery of agent |
US5536243A (en) * | 1994-12-13 | 1996-07-16 | Jeyendran; Rajasingam S. | Time-release insemination device |
US5690952A (en) * | 1995-06-07 | 1997-11-25 | Judy A. Magruder et al. | Implantable system for delivery of fluid-sensitive agents to animals |
US5707663A (en) * | 1993-05-28 | 1998-01-13 | Alza Corporation | Sustained antiepileptic therapy |
US5728088A (en) * | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US5773020A (en) * | 1990-04-25 | 1998-06-30 | Vivus, Inc. | Treatment of erectile dysfunction |
US5800422A (en) * | 1995-06-02 | 1998-09-01 | Alza Corporation | Osmotic device with delayed activation of drug delivery and complete drug release |
US5807306A (en) * | 1992-11-09 | 1998-09-15 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus |
US5817335A (en) * | 1995-05-26 | 1998-10-06 | Alza Corporation | Osmotic device with high drug loading and delayed activation of drug delivery |
US5861166A (en) * | 1991-03-12 | 1999-01-19 | Alza Corporation | Delivery device providing beneficial agent stability |
US5902605A (en) * | 1996-04-18 | 1999-05-11 | Alza Corporation | Drug delivery device with minimal residual drug retention |
US5922353A (en) * | 1995-06-07 | 1999-07-13 | Alza Corporation | Interlocking couplings for osmotic delivery devices |
US5938654A (en) * | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5988169A (en) * | 1996-03-29 | 1999-11-23 | Iotek, Inc. | Vaginal insert and method for treating urogenital disorders |
US6030375A (en) * | 1996-03-29 | 2000-02-29 | Iotek, Inc. | Compressible vaginal insert and method for treating urogenital disorders |
WO2000023663A1 (en) | 1998-10-21 | 2000-04-27 | Reckitt Benckiser (Uk) Limited | Dispensing device |
US6120484A (en) * | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
US6153678A (en) * | 1997-10-06 | 2000-11-28 | Alza Corporation | Injection-moldable composition and article of manufacture comprising same |
US6152943A (en) * | 1998-08-14 | 2000-11-28 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
US6159491A (en) * | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
US6165201A (en) * | 1998-08-14 | 2000-12-26 | Incept Llc | Method and apparatus for in situ formation of hydrogels |
US6179862B1 (en) | 1998-08-14 | 2001-01-30 | Incept Llc | Methods and apparatus for in situ formation of hydrogels |
US6270799B1 (en) | 1997-09-25 | 2001-08-07 | Bayer Aktiengesellscahft | Medicament formulation with a controlled release of an active agent |
US20010041900A1 (en) * | 1999-12-21 | 2001-11-15 | Ovion, Inc. | Occluding device and method of use |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US20020048600A1 (en) * | 1998-11-02 | 2002-04-25 | Padmanabh Bhatt | Controlled delivery of active agents |
US20020071863A1 (en) * | 1999-12-09 | 2002-06-13 | Dong Liang C. | Antiviral medication |
US20030029457A1 (en) * | 1996-12-18 | 2003-02-13 | Callister Jeffrey P. | Contraceptive system and method of use |
US6558362B1 (en) | 1999-02-03 | 2003-05-06 | Bernard Chaffringeon | Disposable device for transferring an active liquid into a body cavity |
US20030125714A1 (en) * | 2001-12-18 | 2003-07-03 | Edgren David Emil | Dosage form for time-varying patterns of drug delivery |
US6605294B2 (en) | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US20030153864A1 (en) * | 2001-10-16 | 2003-08-14 | Bernard Chaffringeon | Disposable device and method for transferring an active liquid into a body cavity |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US20030198619A1 (en) * | 2001-12-19 | 2003-10-23 | Dong Liang C. | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
US20030224051A1 (en) * | 2002-05-31 | 2003-12-04 | Fink Tracy A. | Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
US20030232078A1 (en) * | 2001-12-19 | 2003-12-18 | Dong Liang C. | Formulation & dosage form for the controlled delivery of therapeutic agents |
US20040010000A1 (en) * | 2002-04-29 | 2004-01-15 | Ayer Atul D. | Methods and dosage forms for controlled delivery of oxycodone |
US6706282B1 (en) | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
US20040091529A1 (en) * | 2002-06-26 | 2004-05-13 | David Edgren | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
WO2004043501A1 (en) | 2002-11-09 | 2004-05-27 | Reckitt Benckiser (Uk) Limited | Improvements in or relating to articles |
WO2004048451A2 (en) | 2002-11-26 | 2004-06-10 | Genencor International, Inc. | Optical information carrier comprising immobilized proteorhodopsin |
US20040115262A1 (en) * | 2002-07-29 | 2004-06-17 | Frank Jao | Formulations and dosage forms for controlled delivery of topiramate |
US20040166160A1 (en) * | 2003-01-14 | 2004-08-26 | Ramkumar Subramanian | Methods and dosage forms with modified viscosity layers |
US20040197407A1 (en) * | 2003-02-11 | 2004-10-07 | Ramkumar Subramanian | Methods and dosage forms with modified layer geometry |
US20040219186A1 (en) * | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
WO2004112711A2 (en) | 2003-06-16 | 2004-12-29 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
US20050031546A1 (en) * | 2003-08-06 | 2005-02-10 | Johannes Bartholomaus | Abuse-proffed dosage form |
US20050045183A1 (en) * | 1996-12-18 | 2005-03-03 | Ovion, Inc. | Methods and devices for occluding body lumens and/or for delivering therapeutic agents |
US20050058707A1 (en) * | 2003-08-06 | 2005-03-17 | Iran Reyes | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
US20050069587A1 (en) * | 2003-09-02 | 2005-03-31 | Modi Nishit Bachulal | Novel drug compositions and dosage forms of topiramate |
US20050089570A1 (en) * | 2003-09-26 | 2005-04-28 | Evangeline Cruz | Oros push-stick for controlled delivery of active agents |
US20050106249A1 (en) * | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
US20050112195A1 (en) * | 2003-09-26 | 2005-05-26 | Evangeline Cruz | Drug coating providing high drug loading and methods for providing same |
US20050129765A1 (en) * | 2003-11-14 | 2005-06-16 | Shaoling Li | Controlled release of topiramate in liquid dosage forms |
US20050136108A1 (en) * | 2003-08-22 | 2005-06-23 | Yam Noymi V. | Stepwise delivery of topiramate over prolonged period of time |
US20050152843A1 (en) * | 2002-06-17 | 2005-07-14 | Johannes Bartholomaus | Abuse-proofed dosage form |
US20050158382A1 (en) * | 2003-09-26 | 2005-07-21 | Evangeline Cruz | Controlled release formulations of opioid and nonopioid analgesics |
US20050169992A1 (en) * | 2003-12-23 | 2005-08-04 | Frank Jao | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
US20050175696A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Drug granule coatings that impart smear resistance during mechanical compression |
US20050175697A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Novel drug compositions and dosage forms of topiramate |
US20050175690A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Novel drug compositions and dosage forms |
US20050192616A1 (en) * | 2004-02-02 | 2005-09-01 | Callister Jeffrey P. | Contraceptive with permeable and impermeable components |
US20050232995A1 (en) * | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
US20050234336A1 (en) * | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
US20050232972A1 (en) * | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
US20050236741A1 (en) * | 2004-04-22 | 2005-10-27 | Elisabeth Arkenau | Process for the production of an abuse-proofed solid dosage form |
US20050276850A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Controlled release sodium valproate formulation |
US20050276848A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
US20050287185A1 (en) * | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
US20050288551A1 (en) * | 2004-04-28 | 2005-12-29 | Ams Research Corporation | Endoscopic delivery of medical devices |
US20050287212A1 (en) * | 2004-06-28 | 2005-12-29 | Liang-Chang Dong | Oral delivery system comprising a drug/polymer complex |
US20050287213A1 (en) * | 2004-06-28 | 2005-12-29 | Wong Patrick S | Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents |
US20060002860A1 (en) * | 2004-07-01 | 2006-01-05 | Johannes Bartholomaus | Abuse-proofed oral dosage form |
US20060002859A1 (en) * | 2004-07-01 | 2006-01-05 | Elisabeth Arkenau | Process for production of an abuse-proofed solid dosage form |
US20060009798A1 (en) * | 2004-02-02 | 2006-01-12 | Ams Research Corporation | Methods and devices for occluding body lumens and/or enhancing tissue ingrowth |
US20060039864A1 (en) * | 2004-07-01 | 2006-02-23 | Johannes Bartholomaus | Abuse-proofed oral dosage form |
US20060057206A1 (en) * | 2004-08-19 | 2006-03-16 | Wong Patrick S | Controlled release nanoparticle active agent formulation dosage forms and methods |
US20060189944A1 (en) * | 2005-02-08 | 2006-08-24 | Campbell Patrick K | Spray for fluent materials |
US20060188447A1 (en) * | 2005-02-04 | 2006-08-24 | Elisabeth Arkenau-Maric | Process for the production of an abuse-proofed dosage form |
US20060193914A1 (en) * | 2005-02-04 | 2006-08-31 | Judy Ashworth | Crush resistant delayed-release dosage forms |
US20060233882A1 (en) * | 2005-04-15 | 2006-10-19 | Sowden Harry S | Osmotic dosage form |
US20060257484A1 (en) * | 2005-04-19 | 2006-11-16 | Hwang Stephen S | Combination of tramadol and substances that comprise gabapentin |
US20070003616A1 (en) * | 2003-12-24 | 2007-01-04 | Elisabeth Arkenau-Maric | Process for the production of an abuse-proofed dosage form |
US20070003624A1 (en) * | 2005-06-29 | 2007-01-04 | Shanbhag Anant R | Semi-permeable compositions providing reduced drying time for osmotic dosage forms |
US20070009600A1 (en) * | 1993-05-27 | 2007-01-11 | Edgren David E | Antidepressant dosage form |
US20070031496A1 (en) * | 2005-08-04 | 2007-02-08 | Edgren David E | Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties |
US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
WO2007053698A2 (en) | 2005-10-31 | 2007-05-10 | Alza Corporation | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms |
US20070183979A1 (en) * | 2003-08-06 | 2007-08-09 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US20070183980A1 (en) * | 2003-08-06 | 2007-08-09 | Elisabeth Arkenau-Maric | Dosage form that is safeguarded from abuse |
US20070227544A1 (en) * | 2006-03-30 | 2007-10-04 | Betsy Swann | Methods and devices for deployment into a lumen |
US20070243230A1 (en) * | 2006-03-31 | 2007-10-18 | Forsight Labs, Llc | Nasolacrimal Drainage System Implants for Drug Therapy |
US20070281018A1 (en) * | 2004-09-24 | 2007-12-06 | Abbott Laboratories | Sustained release formulations of opioid and nonopioid analgesics |
US20080114092A1 (en) * | 1998-12-04 | 2008-05-15 | Incept Llc | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof |
WO2008084698A1 (en) | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | Tacrolimus sustained release pharmaceutical composition |
US20080214629A1 (en) * | 2007-02-09 | 2008-09-04 | Scott Bull | Controlled release compositions of tizanidine |
US20090004267A1 (en) * | 2007-03-07 | 2009-01-01 | Gruenenthal Gmbh | Dosage Form with Impeded Abuse |
US20090022798A1 (en) * | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
US20090087484A1 (en) * | 2007-09-28 | 2009-04-02 | Alza Corporation | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
US20090088723A1 (en) * | 2007-09-28 | 2009-04-02 | Accessclosure, Inc. | Apparatus and methods for treating pseudoaneurysms |
US20090098584A1 (en) * | 2005-09-01 | 2009-04-16 | Bristol-Myers Squibb Company | Biomarkers and Methods for Determining Sensitivity to Vascular Endothelial growth factor Receptor-2 Modulators |
US20090104243A1 (en) * | 2007-09-07 | 2009-04-23 | Qlt Plug Delivery, Inc. - Qpdi | Drug cores for sustained release of therapeutic agents |
US20090104248A1 (en) * | 2007-09-07 | 2009-04-23 | Qlt Plug Delivery, Inc. -Qpdi | Lacrimal implants and related methods |
US20090105749A1 (en) * | 2007-09-07 | 2009-04-23 | Qlt Plug Delivery, Inc. - Qpdi | Insertion and extraction tools for lacrimal implants |
US20090118702A1 (en) * | 2004-07-02 | 2009-05-07 | Forsight Labs, Llc | Treatment Medium Delivery Device and Methods for Delivery of Such Treatment Mediums to the Eye Using such a Delivery Device |
US20090123297A1 (en) * | 2007-11-08 | 2009-05-14 | Honeywell International | Microfluidic osmotic pump |
US20090202634A1 (en) * | 2008-01-25 | 2009-08-13 | Grunenthal Gmbh | Pharmaceutical dosage form |
US20090264861A1 (en) * | 2008-02-18 | 2009-10-22 | Qlt Plug Delivery, Inc. | Lacrimal implants and related methods |
US20090280158A1 (en) * | 2008-05-09 | 2009-11-12 | Qlt Plug Delivery, Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
US20090317355A1 (en) * | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
EP2154241A2 (en) | 2008-08-12 | 2010-02-17 | The Regents of the University of Michigan | Cell culture well-plates having inverted colloidal crystal scaffolds |
US20100040672A1 (en) * | 2008-06-09 | 2010-02-18 | Northwestern University | Delivery of therapeutics |
US20100172989A1 (en) * | 2006-01-21 | 2010-07-08 | Abbott Laboratories | Abuse resistant melt extruded formulation having reduced alcohol interaction |
US20100209478A1 (en) * | 2009-02-12 | 2010-08-19 | Sawhney Amarpreet S | Drug delivery through hydrogel plugs |
US20100274204A1 (en) * | 2009-02-23 | 2010-10-28 | Qlt Plug Delivery, Inc. | Lacrimal implants and related methods |
US20110082214A1 (en) * | 2008-05-09 | 2011-04-07 | Gruenthal Gmbh | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
WO2011049694A1 (en) | 2009-10-23 | 2011-04-28 | Conceptus, Inc. | Contraceptive devices |
US20110142936A1 (en) * | 2009-12-15 | 2011-06-16 | Patrick Campbell | Implants and biodegradable fiducial markers |
EP2335691A1 (en) | 2004-05-11 | 2011-06-22 | Bayer Schering Pharma AG | Formulations comprising vardenafil with controlled release of active ingredient |
US20110187017A1 (en) * | 2010-02-03 | 2011-08-04 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
WO2011122524A1 (en) | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | Controlled release pharmaceutical composition |
WO2012025930A3 (en) * | 2010-08-25 | 2012-04-19 | Ocure Ltd. | Medical instruments of treating and/or diagnosing of anorectal disorders, and devices and methods for insertion of such |
WO2013086015A1 (en) | 2011-12-05 | 2013-06-13 | Incept, Llc | Medical organogel processes and compositions |
US9132088B2 (en) | 2008-04-30 | 2015-09-15 | Mati Therapeutics Inc. | Composite lacrimal insert and related methods |
US9138337B2 (en) | 2004-06-30 | 2015-09-22 | Abbott Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
WO2016094646A1 (en) | 2014-12-10 | 2016-06-16 | Incept, Llc | Hydrogel drug delivery implants |
WO2016183296A1 (en) | 2015-05-12 | 2016-11-17 | Incept, Llc | Drug delivery from hydrogels |
US9610271B2 (en) | 2011-08-29 | 2017-04-04 | Mati Therapeutics Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
WO2017091749A1 (en) | 2015-11-25 | 2017-06-01 | Incept, Llc | Shape changing drug delivery devices and methods |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
WO2018058048A1 (en) | 2016-09-23 | 2018-03-29 | Incept, Llc | Intracameral drug delivery depots |
US9974685B2 (en) | 2011-08-29 | 2018-05-22 | Mati Therapeutics | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
USD829390S1 (en) * | 2016-12-23 | 2018-09-25 | Jurox Pty Ltd | Intravaginal device |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
WO2019161307A1 (en) | 2018-02-16 | 2019-08-22 | Esperion Therapeutics, Inc. | Sustained release formulations of bempedoic acid |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10799593B2 (en) | 2008-06-09 | 2020-10-13 | Northwestern University | Nanodiamond particle complexes |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
WO2021029430A1 (en) | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | Oral pharmaceutical composition containing heterocyclic compound |
US11141312B2 (en) | 2007-09-07 | 2021-10-12 | Mati Therapeutics Inc. | Lacrimal implant detection |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US706778A (en) * | 1901-12-03 | 1902-08-12 | Edmund Morse Pond | Medicated tampon. |
US2643027A (en) * | 1947-07-26 | 1953-06-23 | Mearl M Fink | Uniformly collapsible tube |
US2687729A (en) * | 1951-03-07 | 1954-08-31 | William V Slavin | Medical appliance |
US2959250A (en) * | 1958-09-15 | 1960-11-08 | Salvador A Minera | Lubricant dispenser |
US3102540A (en) * | 1962-06-19 | 1963-09-03 | Itzhak E Bentov | Means for administering medicine |
US3202324A (en) * | 1961-10-06 | 1965-08-24 | Fr Des Lab Labaz Sa Soc | Plastic bags for injectable solutions |
US3490454A (en) * | 1966-10-21 | 1970-01-20 | United Merchants & Mfg | Catamenial products having a coating of rupturable microcapsules containing medicants |
US3559646A (en) * | 1968-08-16 | 1971-02-02 | Joseph Mullan | Tampon |
US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US3760805A (en) * | 1971-01-13 | 1973-09-25 | Alza Corp | Osmotic dispenser with collapsible supply container |
-
1973
- 1973-07-09 US US377350A patent/US3865108A/en not_active Expired - Lifetime
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US706778A (en) * | 1901-12-03 | 1902-08-12 | Edmund Morse Pond | Medicated tampon. |
US2643027A (en) * | 1947-07-26 | 1953-06-23 | Mearl M Fink | Uniformly collapsible tube |
US2687729A (en) * | 1951-03-07 | 1954-08-31 | William V Slavin | Medical appliance |
US2959250A (en) * | 1958-09-15 | 1960-11-08 | Salvador A Minera | Lubricant dispenser |
US3202324A (en) * | 1961-10-06 | 1965-08-24 | Fr Des Lab Labaz Sa Soc | Plastic bags for injectable solutions |
US3102540A (en) * | 1962-06-19 | 1963-09-03 | Itzhak E Bentov | Means for administering medicine |
US3490454A (en) * | 1966-10-21 | 1970-01-20 | United Merchants & Mfg | Catamenial products having a coating of rupturable microcapsules containing medicants |
US3559646A (en) * | 1968-08-16 | 1971-02-02 | Joseph Mullan | Tampon |
US3760805A (en) * | 1971-01-13 | 1973-09-25 | Alza Corp | Osmotic dispenser with collapsible supply container |
US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
Cited By (387)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4005699A (en) * | 1974-10-09 | 1977-02-01 | Louis Bucalo | Methods and apparatus for use in magnetic treatment of the body |
US3946734A (en) * | 1975-02-19 | 1976-03-30 | The United States Of America As Represented By The Secretary Of State | Apparatus for controlling the release of a drug |
US4185618A (en) * | 1976-01-05 | 1980-01-29 | Population Research, Inc. | Promotion of fibrous tissue growth in fallopian tubes for female sterilization |
US4041948A (en) * | 1976-07-26 | 1977-08-16 | Johnson & Johnson | Digital tampon |
US4207893A (en) * | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
US4192308A (en) * | 1977-10-25 | 1980-03-11 | Alza Corporation | Device using prestretched polymer for dispensing medication |
US4203440A (en) * | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
US4304232A (en) * | 1979-03-14 | 1981-12-08 | Alza Corporation | Unit system having multiplicity of means for dispensing useful agent |
US4237893A (en) * | 1979-11-28 | 1980-12-09 | Alza Corporation | Cervical dilator |
US4299222A (en) * | 1980-01-08 | 1981-11-10 | Alza Corporation | Self-contained suction pump |
US4360013A (en) * | 1980-04-21 | 1982-11-23 | Minnesota Mining And Manufacturing Company | Polymeric acid contraceptive devices |
US4350271A (en) * | 1980-08-22 | 1982-09-21 | Alza Corporation | Water absorbing fluid dispenser |
US4455144A (en) * | 1980-12-04 | 1984-06-19 | Alza Corporation | Dispenser constructed with semipermeable polymer-hydrophilic polymer wall |
US4367741A (en) * | 1980-12-22 | 1983-01-11 | Alza Corporation | Dispenser powered by cross-linked hydrophilic polymer grafted to hydrophilic polymer |
EP0168507A1 (en) * | 1981-04-27 | 1986-01-22 | Repromed, Inc. | Osmotic cervical dilator |
US4764380A (en) * | 1982-03-22 | 1988-08-16 | Alza Corporation | Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills |
WO1984000494A1 (en) * | 1982-07-26 | 1984-02-16 | Health Prod Res | Dilatation device for the cervix |
DE3634864A1 (en) * | 1983-11-02 | 1988-04-14 | Alza Corp | DELIVERY DEVICE FOR RELEASING A TEMPERATURE-RELEVANT MEASURE |
US4692326A (en) * | 1984-03-21 | 1987-09-08 | Alza Corporation | Dispenser comprising inner positioned soft or hard capsule |
US4663149A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising inner and outer walls functioning as cooperative unit |
US4716031A (en) * | 1984-03-21 | 1987-12-29 | Alza Corporation | Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug |
US4663148A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising telescopically engaging members |
GB2155889A (en) * | 1984-03-21 | 1985-10-02 | Alza Corp | Dispenser-capsule |
US4800056A (en) * | 1984-03-21 | 1989-01-24 | Alza Corporation | Process for making dispenser with cooperating elements |
US4814180A (en) * | 1984-03-21 | 1989-03-21 | Alza Corporation | Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container |
FR2561628A1 (en) * | 1984-03-21 | 1985-09-27 | Alza Corp | DEVICE FOR DELIVERING SUBSTANCES WITH SEVERAL COMPONENTS OPERATING IN INTEGRATED UNIT SYSTEM |
US4778607A (en) * | 1984-04-30 | 1988-10-18 | Marathon Oil Company | Method of diluting a concentrated polymer solution for use in a hydrocarbon recovery process |
US4851232A (en) * | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US4871542A (en) * | 1987-04-30 | 1989-10-03 | Ferring Service Center, N.V. | Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract |
US5938654A (en) * | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5391381A (en) * | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
US5236689A (en) * | 1987-06-25 | 1993-08-17 | Alza Corporation | Multi-unit delivery system |
US5340590A (en) * | 1987-06-25 | 1994-08-23 | Alza Corporation | Delivery system with bilayer osmotic engine |
US4846279A (en) * | 1988-01-13 | 1989-07-11 | Marathon Oil Company | Method and means for introducing treatment fluid into a well bore |
US4996060A (en) * | 1988-03-25 | 1991-02-26 | Alza Corporation | Device comprising liner for protecting fluid sensitive medicament |
AU621588B2 (en) * | 1988-03-25 | 1992-03-19 | Alza Corporation | Device comprising means for protecting and dispensing fluid sensitive medicament |
US4855141A (en) * | 1988-03-25 | 1989-08-08 | Alza Corporation | Device comprising means for protecting and dispensing fluid sensitive medicament |
US4959218A (en) * | 1988-03-25 | 1990-09-25 | Alza Corporation | Method for delivering somatotropin to an animal |
US5019397A (en) * | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
US5006346A (en) * | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US5024842A (en) * | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US4931285A (en) * | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US5728088A (en) * | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US5630808A (en) * | 1988-12-13 | 1997-05-20 | Alza Corporation | Delivery system comprising means for governing fluid into the system and for restricting fluid into the system |
US5110596A (en) * | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
US5135523A (en) * | 1988-12-13 | 1992-08-04 | Alza Corporation | Delivery system for administering agent to ruminants and swine |
US5059423A (en) * | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
US5057318A (en) * | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
US5174999A (en) * | 1988-12-13 | 1992-12-29 | Alza Corporation | Delivery system comprising fluid ingress and drug egress |
US6180129B1 (en) | 1988-12-13 | 2001-01-30 | Alza Corporation | Polyurethane-containing delivery systems |
US5980509A (en) * | 1988-12-13 | 1999-11-09 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US5037420A (en) * | 1988-12-13 | 1991-08-06 | Alza Corporation | Delivery system comprising two sections for delivering somatotropin |
US5320616A (en) * | 1988-12-13 | 1994-06-14 | Alza Corporation | Delivery system comprising first walled section and second walled section united by fusion, adhesion or telescopic engagement |
US5714160A (en) * | 1988-12-13 | 1998-02-03 | Alza Corporation | Delivery system comprising means for governing fluid ingress into the system |
US4976966A (en) * | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
US5273752A (en) * | 1989-07-18 | 1993-12-28 | Alza Corporation | Controlled release dispenser comprising beneficial agent |
US5126142A (en) * | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5035897A (en) * | 1989-09-05 | 1991-07-30 | Alza Corporation | Dosage form for delivering soluble or insoluble drugs |
US5474785A (en) * | 1990-01-24 | 1995-12-12 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
US5024663A (en) * | 1990-02-21 | 1991-06-18 | Alza Corporation | Self-contained suction pump |
US5773020A (en) * | 1990-04-25 | 1998-06-30 | Vivus, Inc. | Treatment of erectile dysfunction |
US5628730A (en) * | 1990-06-15 | 1997-05-13 | Cortrak Medical, Inc. | Phoretic balloon catheter with hydrogel coating |
US5286254A (en) * | 1990-06-15 | 1994-02-15 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
US5282785A (en) * | 1990-06-15 | 1994-02-01 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
US5498238A (en) * | 1990-06-15 | 1996-03-12 | Cortrak Medical, Inc. | Simultaneous angioplasty and phoretic drug delivery |
US5238687A (en) * | 1990-07-11 | 1993-08-24 | Alza Corporation | Delivery device with a protective sleeve |
US5180591A (en) * | 1990-07-11 | 1993-01-19 | Alza Corporation | Delivery device with a protective sleeve |
US5234693A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234692A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234694A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Method for increasing feed efficiency in animals |
US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5861166A (en) * | 1991-03-12 | 1999-01-19 | Alza Corporation | Delivery device providing beneficial agent stability |
US5458568A (en) * | 1991-05-24 | 1995-10-17 | Cortrak Medical, Inc. | Porous balloon for selective dilatation and drug delivery |
US5198229A (en) * | 1991-06-05 | 1993-03-30 | Alza Corporation | Self-retaining gastrointestinal delivery device |
USRE35601E (en) * | 1991-06-12 | 1997-09-02 | Alza Corporation | Delivery device providing beneficial agent stability |
US5137727A (en) * | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
US5240713A (en) * | 1991-09-27 | 1993-08-31 | Alza Corporation | Dual rate agent delivery device |
US5312390A (en) * | 1992-01-10 | 1994-05-17 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5223265A (en) * | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US5807306A (en) * | 1992-11-09 | 1998-09-15 | Cortrak Medical, Inc. | Polymer matrix drug delivery apparatus |
US8084059B2 (en) | 1993-05-27 | 2011-12-27 | Alza Corporation | Antidepressant dosage form |
JP2008069177A (en) * | 1993-05-27 | 2008-03-27 | Alza Corp | Antidepressant dosage form |
US20070009600A1 (en) * | 1993-05-27 | 2007-01-11 | Edgren David E | Antidepressant dosage form |
US5980943A (en) * | 1993-05-28 | 1999-11-09 | Alza Corporation | Sustained antiepileptic therapy |
US6287598B1 (en) | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
US5707663A (en) * | 1993-05-28 | 1998-01-13 | Alza Corporation | Sustained antiepileptic therapy |
US5498255A (en) * | 1993-08-17 | 1996-03-12 | Alza Corporation | Osmotic device for protracted pulsatile delivery of agent |
US5536243A (en) * | 1994-12-13 | 1996-07-16 | Jeyendran; Rajasingam S. | Time-release insemination device |
US5817335A (en) * | 1995-05-26 | 1998-10-06 | Alza Corporation | Osmotic device with high drug loading and delayed activation of drug delivery |
US5800422A (en) * | 1995-06-02 | 1998-09-01 | Alza Corporation | Osmotic device with delayed activation of drug delivery and complete drug release |
US5922353A (en) * | 1995-06-07 | 1999-07-13 | Alza Corporation | Interlocking couplings for osmotic delivery devices |
US5690952A (en) * | 1995-06-07 | 1997-11-25 | Judy A. Magruder et al. | Implantable system for delivery of fluid-sensitive agents to animals |
US5871770A (en) * | 1995-06-07 | 1999-02-16 | Alza Corporation | Implantable system for delivery of fluid-sensitive agents to animals |
US5988169A (en) * | 1996-03-29 | 1999-11-23 | Iotek, Inc. | Vaginal insert and method for treating urogenital disorders |
US6030375A (en) * | 1996-03-29 | 2000-02-29 | Iotek, Inc. | Compressible vaginal insert and method for treating urogenital disorders |
US5902605A (en) * | 1996-04-18 | 1999-05-11 | Alza Corporation | Drug delivery device with minimal residual drug retention |
US8113205B2 (en) | 1996-12-18 | 2012-02-14 | Conceptus, Inc. | Contraceptive system and method of use |
US7398780B2 (en) | 1996-12-18 | 2008-07-15 | Ams Research Corporation | Contraceptive system and method of use |
US20080135054A1 (en) * | 1996-12-18 | 2008-06-12 | Jeffrey P. Callister | Contraceptive system and method of use |
US7694683B2 (en) * | 1996-12-18 | 2010-04-13 | Conceptus, Inc. | Methods and devices for occluding body lumens and/or for delivering therapeutic agents |
US8707957B2 (en) | 1996-12-18 | 2014-04-29 | Bayer Essure Inc. | Contraceptive system and method of use |
US20030029457A1 (en) * | 1996-12-18 | 2003-02-13 | Callister Jeffrey P. | Contraceptive system and method of use |
US20050045183A1 (en) * | 1996-12-18 | 2005-03-03 | Ovion, Inc. | Methods and devices for occluding body lumens and/or for delivering therapeutic agents |
US6270799B1 (en) | 1997-09-25 | 2001-08-07 | Bayer Aktiengesellscahft | Medicament formulation with a controlled release of an active agent |
US6153678A (en) * | 1997-10-06 | 2000-11-28 | Alza Corporation | Injection-moldable composition and article of manufacture comprising same |
US20070288052A1 (en) * | 1998-08-14 | 2007-12-13 | Incept Llc | In situ materials formation |
US20080017201A1 (en) * | 1998-08-14 | 2008-01-24 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US20100119451A1 (en) * | 1998-08-14 | 2010-05-13 | Incept, Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US7776063B2 (en) | 1998-08-14 | 2010-08-17 | Incept Llc | In situ materials formation |
US7780980B2 (en) | 1998-08-14 | 2010-08-24 | Incept, Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US7914541B2 (en) | 1998-08-14 | 2011-03-29 | Incept, Llc | In situ materials formation |
US6605294B2 (en) | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US20050080445A1 (en) * | 1998-08-14 | 2005-04-14 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
US6152943A (en) * | 1998-08-14 | 2000-11-28 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US8105622B2 (en) | 1998-08-14 | 2012-01-31 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US20080279944A1 (en) * | 1998-08-14 | 2008-11-13 | Incept Llc | Composite hydrogel drug delivery systems |
US7413752B2 (en) | 1998-08-14 | 2008-08-19 | Incept Llc | Composite hydrogel drug delivery systems |
US6673093B1 (en) | 1998-08-14 | 2004-01-06 | Incept Llc | Methods and apparatus for in situ formation of hydrogels |
US6165201A (en) * | 1998-08-14 | 2000-12-26 | Incept Llc | Method and apparatus for in situ formation of hydrogels |
US20040009205A1 (en) * | 1998-08-14 | 2004-01-15 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US20040033264A1 (en) * | 1998-08-14 | 2004-02-19 | Incept Llc | Composite hydrogel drug delivery systems |
US6179862B1 (en) | 1998-08-14 | 2001-01-30 | Incept Llc | Methods and apparatus for in situ formation of hydrogels |
US20080132936A1 (en) * | 1998-08-14 | 2008-06-05 | Incept Llc | In situ materials formation |
US6379373B1 (en) | 1998-08-14 | 2002-04-30 | Confluent Surgical, Inc. | Methods and apparatus for intraluminal deposition of hydrogels |
US7220270B2 (en) | 1998-08-14 | 2007-05-22 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
US20060193899A1 (en) * | 1998-08-14 | 2006-08-31 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US7648713B2 (en) | 1998-08-14 | 2010-01-19 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US9254267B2 (en) | 1998-08-14 | 2016-02-09 | Incept, Llc | Composite hydrogel drug delivery systems |
WO2000023663A1 (en) | 1998-10-21 | 2000-04-27 | Reckitt Benckiser (Uk) Limited | Dispensing device |
US6510561B1 (en) | 1998-10-21 | 2003-01-28 | Reckitt Benckiser (Uk) Limited | Dispensing device |
EP1652516A2 (en) | 1998-11-02 | 2006-05-03 | ALZA Corporation | Osmotic controlled delivery of active agents |
US20020048600A1 (en) * | 1998-11-02 | 2002-04-25 | Padmanabh Bhatt | Controlled delivery of active agents |
US6855334B2 (en) | 1998-11-02 | 2005-02-15 | Alta Corporation | Controlled delivery of active agents |
US6706282B1 (en) | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
US20080114092A1 (en) * | 1998-12-04 | 2008-05-15 | Incept Llc | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof |
US6596314B2 (en) | 1998-12-23 | 2003-07-22 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US6558362B1 (en) | 1999-02-03 | 2003-05-06 | Bernard Chaffringeon | Disposable device for transferring an active liquid into a body cavity |
US20030191439A1 (en) * | 1999-02-03 | 2003-10-09 | Bernard Chaffringeon | Disposable device for transferring an active liquid into a body cavity |
US6159491A (en) * | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
US6120484A (en) * | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
US20020071863A1 (en) * | 1999-12-09 | 2002-06-13 | Dong Liang C. | Antiviral medication |
US20010041900A1 (en) * | 1999-12-21 | 2001-11-15 | Ovion, Inc. | Occluding device and method of use |
US20040219186A1 (en) * | 2001-08-16 | 2004-11-04 | Ayres James W. | Expandable gastric retention device |
US20030153864A1 (en) * | 2001-10-16 | 2003-08-14 | Bernard Chaffringeon | Disposable device and method for transferring an active liquid into a body cavity |
US20070255232A1 (en) * | 2001-10-16 | 2007-11-01 | Bernard Chaffringeon | Disposable device and method for transferring an active liquid into a body cavity |
US20070207204A1 (en) * | 2001-12-18 | 2007-09-06 | Alza Corporation | Dosage Form for Time-Varying Patterns of Drug Delivery |
US20030125714A1 (en) * | 2001-12-18 | 2003-07-03 | Edgren David Emil | Dosage form for time-varying patterns of drug delivery |
US20030198619A1 (en) * | 2001-12-19 | 2003-10-23 | Dong Liang C. | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
US20030232078A1 (en) * | 2001-12-19 | 2003-12-18 | Dong Liang C. | Formulation & dosage form for the controlled delivery of therapeutic agents |
US20040010000A1 (en) * | 2002-04-29 | 2004-01-15 | Ayer Atul D. | Methods and dosage forms for controlled delivery of oxycodone |
US20050106249A1 (en) * | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
US20030224051A1 (en) * | 2002-05-31 | 2003-12-04 | Fink Tracy A. | Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
US20100260833A1 (en) * | 2002-06-17 | 2010-10-14 | Grunenthal Gmbh | Abuse-proofed dosage form |
US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
US20050152843A1 (en) * | 2002-06-17 | 2005-07-14 | Johannes Bartholomaus | Abuse-proofed dosage form |
US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
US20040091529A1 (en) * | 2002-06-26 | 2004-05-13 | David Edgren | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
US20090202631A1 (en) * | 2002-07-29 | 2009-08-13 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
US9393192B2 (en) | 2002-07-29 | 2016-07-19 | Alza Corporation | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
US20050232995A1 (en) * | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
US20040115262A1 (en) * | 2002-07-29 | 2004-06-17 | Frank Jao | Formulations and dosage forms for controlled delivery of topiramate |
WO2004043501A1 (en) | 2002-11-09 | 2004-05-27 | Reckitt Benckiser (Uk) Limited | Improvements in or relating to articles |
US8535653B2 (en) | 2002-11-09 | 2013-09-17 | Reckitt Benckiser (Uk) Limited | Articles for the release or emanation of vapors |
US20060140901A1 (en) * | 2002-11-09 | 2006-06-29 | Reckitt Benckiser (Uk) Limited | Articles |
WO2004048451A2 (en) | 2002-11-26 | 2004-06-10 | Genencor International, Inc. | Optical information carrier comprising immobilized proteorhodopsin |
US20040166160A1 (en) * | 2003-01-14 | 2004-08-26 | Ramkumar Subramanian | Methods and dosage forms with modified viscosity layers |
US20040197407A1 (en) * | 2003-02-11 | 2004-10-07 | Ramkumar Subramanian | Methods and dosage forms with modified layer geometry |
EP2535042A1 (en) | 2003-06-16 | 2012-12-19 | ANDRX Pharmaceuticals LLC. | Oral sustained-release composition comprising a macrolide |
US20090124563A1 (en) * | 2003-06-16 | 2009-05-14 | Boying Li | Oral extended-release composition |
WO2004112711A2 (en) | 2003-06-16 | 2004-12-29 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
EP2529730A1 (en) | 2003-06-16 | 2012-12-05 | ANDRX Pharmaceuticals LLC. | Oral sustained-release composition |
US8628797B2 (en) | 2003-06-16 | 2014-01-14 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
JP2007521081A (en) * | 2003-06-27 | 2007-08-02 | エイエムエス・リサーチ・コーポレーション | Method and apparatus for occlusion of body lumens and / or delivery of therapeutic agents |
KR101200642B1 (en) | 2003-06-27 | 2012-11-12 | 콘셉투스 인코포레이티드 | Methods and devices for occluding body lumens and/or for delivering therapeutic agents |
US8114383B2 (en) | 2003-08-06 | 2012-02-14 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
US20070048228A1 (en) * | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US8309060B2 (en) | 2003-08-06 | 2012-11-13 | Grunenthal Gmbh | Abuse-proofed dosage form |
US20050058707A1 (en) * | 2003-08-06 | 2005-03-17 | Iran Reyes | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
US20070183979A1 (en) * | 2003-08-06 | 2007-08-09 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US20070183980A1 (en) * | 2003-08-06 | 2007-08-09 | Elisabeth Arkenau-Maric | Dosage form that is safeguarded from abuse |
US20060193782A1 (en) * | 2003-08-06 | 2006-08-31 | Johannes Bartholomaus | Abuse-proofed dosage form |
US20080247959A1 (en) * | 2003-08-06 | 2008-10-09 | Grunenthal Gmbh | Form of administration secured against misuse |
US20050031546A1 (en) * | 2003-08-06 | 2005-02-10 | Johannes Bartholomaus | Abuse-proffed dosage form |
US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
US20080311049A1 (en) * | 2003-08-06 | 2008-12-18 | Grunenthal Gmbh | Abuse-proof dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US8420056B2 (en) | 2003-08-06 | 2013-04-16 | Grunenthal Gmbh | Abuse-proofed dosage form |
US8192722B2 (en) | 2003-08-06 | 2012-06-05 | Grunenthal Gmbh | Abuse-proof dosage form |
US20050136108A1 (en) * | 2003-08-22 | 2005-06-23 | Yam Noymi V. | Stepwise delivery of topiramate over prolonged period of time |
US20050069587A1 (en) * | 2003-09-02 | 2005-03-31 | Modi Nishit Bachulal | Novel drug compositions and dosage forms of topiramate |
US8246986B2 (en) | 2003-09-26 | 2012-08-21 | Alza Corporation | Drug coating providing high drug loading |
US20050112195A1 (en) * | 2003-09-26 | 2005-05-26 | Evangeline Cruz | Drug coating providing high drug loading and methods for providing same |
US20050089570A1 (en) * | 2003-09-26 | 2005-04-28 | Evangeline Cruz | Oros push-stick for controlled delivery of active agents |
US20050158382A1 (en) * | 2003-09-26 | 2005-07-21 | Evangeline Cruz | Controlled release formulations of opioid and nonopioid analgesics |
US8226979B2 (en) | 2003-09-26 | 2012-07-24 | Alza Corporation | Drug coating providing high drug loading and methods for providing the same |
US20060251721A1 (en) * | 2003-09-26 | 2006-11-09 | Evangeline Cruz | Controlled release formulations of opioid and nonopioid analgesics |
US20050129765A1 (en) * | 2003-11-14 | 2005-06-16 | Shaoling Li | Controlled release of topiramate in liquid dosage forms |
US20050169992A1 (en) * | 2003-12-23 | 2005-08-04 | Frank Jao | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
US20070003616A1 (en) * | 2003-12-24 | 2007-01-04 | Elisabeth Arkenau-Maric | Process for the production of an abuse-proofed dosage form |
US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US20050175697A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Novel drug compositions and dosage forms of topiramate |
US20050175690A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Novel drug compositions and dosage forms |
US20050175696A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Drug granule coatings that impart smear resistance during mechanical compression |
US20050192616A1 (en) * | 2004-02-02 | 2005-09-01 | Callister Jeffrey P. | Contraceptive with permeable and impermeable components |
US9713549B2 (en) | 2004-02-02 | 2017-07-25 | Bayer Healthcare Llc | Contraceptive with permeable and impermeable components |
US20060009798A1 (en) * | 2004-02-02 | 2006-01-12 | Ams Research Corporation | Methods and devices for occluding body lumens and/or enhancing tissue ingrowth |
US20050234336A1 (en) * | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
US20050232972A1 (en) * | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
US20100040670A1 (en) * | 2004-04-15 | 2010-02-18 | Qlt Plug Delivery, Inc. | Drug delivery via ocular implant |
US9463114B2 (en) | 2004-04-15 | 2016-10-11 | Mati Therapeutics Inc. | Punctal plug with active agent |
US20050236741A1 (en) * | 2004-04-22 | 2005-10-27 | Elisabeth Arkenau | Process for the production of an abuse-proofed solid dosage form |
US20080317854A1 (en) * | 2004-04-22 | 2008-12-25 | Grunenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
US20050288551A1 (en) * | 2004-04-28 | 2005-12-29 | Ams Research Corporation | Endoscopic delivery of medical devices |
US20100168514A1 (en) * | 2004-04-28 | 2010-07-01 | Callister Jeffrey P | Endoscopic delivery of medical devices |
EP2335691A1 (en) | 2004-05-11 | 2011-06-22 | Bayer Schering Pharma AG | Formulations comprising vardenafil with controlled release of active ingredient |
US7713550B2 (en) | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
US20050276848A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
US20050276850A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Controlled release sodium valproate formulation |
US20050287185A1 (en) * | 2004-06-23 | 2005-12-29 | David Wong | Extended release oxybutynin formulation |
US20050287213A1 (en) * | 2004-06-28 | 2005-12-29 | Wong Patrick S | Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents |
US20050287212A1 (en) * | 2004-06-28 | 2005-12-29 | Liang-Chang Dong | Oral delivery system comprising a drug/polymer complex |
US9566373B2 (en) | 2004-06-30 | 2017-02-14 | Abbott Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US9138337B2 (en) | 2004-06-30 | 2015-09-22 | Abbott Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US20060039864A1 (en) * | 2004-07-01 | 2006-02-23 | Johannes Bartholomaus | Abuse-proofed oral dosage form |
US20080248113A1 (en) * | 2004-07-01 | 2008-10-09 | Grunenthal Gmbh | Abuse-proofed oral dosage form |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
US8114384B2 (en) | 2004-07-01 | 2012-02-14 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
US20060002860A1 (en) * | 2004-07-01 | 2006-01-05 | Johannes Bartholomaus | Abuse-proofed oral dosage form |
US20060002859A1 (en) * | 2004-07-01 | 2006-01-05 | Elisabeth Arkenau | Process for production of an abuse-proofed solid dosage form |
US20080312264A1 (en) * | 2004-07-01 | 2008-12-18 | Grunenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
US8323889B2 (en) | 2004-07-01 | 2012-12-04 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
US20090118702A1 (en) * | 2004-07-02 | 2009-05-07 | Forsight Labs, Llc | Treatment Medium Delivery Device and Methods for Delivery of Such Treatment Mediums to the Eye Using such a Delivery Device |
US7922702B2 (en) | 2004-07-02 | 2011-04-12 | Qlt Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
US9180045B2 (en) | 2004-07-02 | 2015-11-10 | Mati Therapeutics Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
US10610407B2 (en) | 2004-07-02 | 2020-04-07 | Mati Therapeutics Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such delivery device |
US9820884B2 (en) | 2004-07-02 | 2017-11-21 | Mati Therapeutics Inc. | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such delivery device |
US20060057206A1 (en) * | 2004-08-19 | 2006-03-16 | Wong Patrick S | Controlled release nanoparticle active agent formulation dosage forms and methods |
US20070281018A1 (en) * | 2004-09-24 | 2007-12-06 | Abbott Laboratories | Sustained release formulations of opioid and nonopioid analgesics |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
US20080311197A1 (en) * | 2005-02-04 | 2008-12-18 | Grunenthal Gmbh | Process for the production of an abuse-proofed dosage form |
US20060188447A1 (en) * | 2005-02-04 | 2006-08-24 | Elisabeth Arkenau-Maric | Process for the production of an abuse-proofed dosage form |
US20060193914A1 (en) * | 2005-02-04 | 2006-08-31 | Judy Ashworth | Crush resistant delayed-release dosage forms |
US20080311187A1 (en) * | 2005-02-04 | 2008-12-18 | Grunenthal Gmbh | Crush resistan delayed-release dosage form |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
US20100151028A1 (en) * | 2005-02-04 | 2010-06-17 | Grunenthal Gmbh | Crush resistant delayed-release dosage forms |
US20060189944A1 (en) * | 2005-02-08 | 2006-08-24 | Campbell Patrick K | Spray for fluent materials |
US20100057122A1 (en) * | 2005-02-08 | 2010-03-04 | Confluent Surgical, Inc | Spray for fluent materials |
US7611494B2 (en) | 2005-02-08 | 2009-11-03 | Confluent Surgical, Inc. | Spray for fluent materials |
US8888749B2 (en) | 2005-02-08 | 2014-11-18 | Confluent Surgical, Inc. | Spray for fluent materials |
US8152777B2 (en) | 2005-02-08 | 2012-04-10 | Confluent Surgical, Inc. | Spray for fluent materials |
US20060233882A1 (en) * | 2005-04-15 | 2006-10-19 | Sowden Harry S | Osmotic dosage form |
US20060257484A1 (en) * | 2005-04-19 | 2006-11-16 | Hwang Stephen S | Combination of tramadol and substances that comprise gabapentin |
US20070003624A1 (en) * | 2005-06-29 | 2007-01-04 | Shanbhag Anant R | Semi-permeable compositions providing reduced drying time for osmotic dosage forms |
US20070031496A1 (en) * | 2005-08-04 | 2007-02-08 | Edgren David E | Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties |
US20090098584A1 (en) * | 2005-09-01 | 2009-04-16 | Bristol-Myers Squibb Company | Biomarkers and Methods for Determining Sensitivity to Vascular Endothelial growth factor Receptor-2 Modulators |
WO2007053698A2 (en) | 2005-10-31 | 2007-05-10 | Alza Corporation | Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms |
US20090221621A1 (en) * | 2005-10-31 | 2009-09-03 | Alza Corporation | Methods of Reducing Alcohol-Induced Dose Dumping for Opioid Sustained Release Oral Dosage Forms |
US20100172989A1 (en) * | 2006-01-21 | 2010-07-08 | Abbott Laboratories | Abuse resistant melt extruded formulation having reduced alcohol interaction |
US20090317355A1 (en) * | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
US8707958B2 (en) | 2006-03-30 | 2014-04-29 | Bayer Essure Inc. | Methods and devices for deployment into a lumen |
US8235047B2 (en) | 2006-03-30 | 2012-08-07 | Conceptus, Inc. | Methods and devices for deployment into a lumen |
US20070227544A1 (en) * | 2006-03-30 | 2007-10-04 | Betsy Swann | Methods and devices for deployment into a lumen |
US10300014B2 (en) | 2006-03-31 | 2019-05-28 | Mati Therapeutics Inc. | Nasolacrimal drainage system implants for drug therapy |
US20070243230A1 (en) * | 2006-03-31 | 2007-10-18 | Forsight Labs, Llc | Nasolacrimal Drainage System Implants for Drug Therapy |
US9610194B2 (en) | 2006-03-31 | 2017-04-04 | Mati Therapeutics Inc. | Drug delivery methods, structures, and compositions for nasolacrimal system |
US8691265B2 (en) | 2006-03-31 | 2014-04-08 | Mati Therapeutics, Inc. | Drug delivery methods, structures, and compositions for nasolacrimal system |
US8795711B2 (en) | 2006-03-31 | 2014-08-05 | Mati Therapeutics Inc. | Drug delivery methods, structures, and compositions for nasolacrimal system |
US11406592B2 (en) | 2006-03-31 | 2022-08-09 | Mati Therapeutics Inc. | Drug delivery methods, structures, and compositions for nasolacrimal system |
US9168222B2 (en) | 2006-03-31 | 2015-10-27 | Mati Therapeutics Inc. | Nasolacrimal drainage system implants for drug therapy |
US8747884B2 (en) | 2006-03-31 | 2014-06-10 | Mati Therapeutics Inc. | Nasolacrimal drainage system implants for drug therapy |
US10383817B2 (en) | 2006-03-31 | 2019-08-20 | Mati Therapeutics Inc. | Nasolacrimal drainage system implants for drug therapy |
US7998497B2 (en) | 2006-03-31 | 2011-08-16 | Qlt Inc. | Nasolacrimal drainage system implants for drug therapy |
US9849082B2 (en) | 2006-03-31 | 2017-12-26 | Mati Therapeutics Inc. | Nasolacrimal drainage system implants for drug therapy |
US10874606B2 (en) | 2006-03-31 | 2020-12-29 | Mati Therapeutics Inc. | Nasolacrimal drainage system implants for drug therapy |
US20090011018A1 (en) * | 2006-12-28 | 2009-01-08 | Astellas Pharma Inc., | Sustained release formulation for tacrolimus |
WO2008084698A1 (en) | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | Tacrolimus sustained release pharmaceutical composition |
US8524749B2 (en) | 2007-02-09 | 2013-09-03 | Alza Corporation | Controlled release compositions of tizanidine |
US20080214629A1 (en) * | 2007-02-09 | 2008-09-04 | Scott Bull | Controlled release compositions of tizanidine |
US8722086B2 (en) | 2007-03-07 | 2014-05-13 | Gruenenthal Gmbh | Dosage form with impeded abuse |
US20090004267A1 (en) * | 2007-03-07 | 2009-01-01 | Gruenenthal Gmbh | Dosage Form with Impeded Abuse |
US20090022798A1 (en) * | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
US8702643B2 (en) | 2007-09-07 | 2014-04-22 | Mati Therapeutics, Inc. | Lacrimal implants and related methods |
US20090104248A1 (en) * | 2007-09-07 | 2009-04-23 | Qlt Plug Delivery, Inc. -Qpdi | Lacrimal implants and related methods |
US8333726B2 (en) | 2007-09-07 | 2012-12-18 | Qlt Inc. | Lacrimal implants and related methods |
US8628792B2 (en) | 2007-09-07 | 2014-01-14 | Mati Therapeutics, Inc. | Drug cores for sustained release of therapeutic agents |
US10434009B2 (en) | 2007-09-07 | 2019-10-08 | Mati Therapeutics Inc. | Lacrimal implants and related methods |
US11951038B2 (en) | 2007-09-07 | 2024-04-09 | Mati Therapeutics Inc. | Lacrimal implants and related methods |
US11141312B2 (en) | 2007-09-07 | 2021-10-12 | Mati Therapeutics Inc. | Lacrimal implant detection |
US9445944B2 (en) | 2007-09-07 | 2016-09-20 | Mati Therapeutics Inc. | Lacrimal implants and related methods |
US20090104243A1 (en) * | 2007-09-07 | 2009-04-23 | Qlt Plug Delivery, Inc. - Qpdi | Drug cores for sustained release of therapeutic agents |
US20090105749A1 (en) * | 2007-09-07 | 2009-04-23 | Qlt Plug Delivery, Inc. - Qpdi | Insertion and extraction tools for lacrimal implants |
US20090088723A1 (en) * | 2007-09-28 | 2009-04-02 | Accessclosure, Inc. | Apparatus and methods for treating pseudoaneurysms |
US20090087484A1 (en) * | 2007-09-28 | 2009-04-02 | Alza Corporation | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
US8394644B2 (en) * | 2007-11-08 | 2013-03-12 | Honeywell International Inc. | Microfluidic osmotic pump |
US20090123297A1 (en) * | 2007-11-08 | 2009-05-14 | Honeywell International | Microfluidic osmotic pump |
US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
US20090202634A1 (en) * | 2008-01-25 | 2009-08-13 | Grunenthal Gmbh | Pharmaceutical dosage form |
US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
US9216108B2 (en) | 2008-02-18 | 2015-12-22 | Mati Therapeutics Inc. | Lacrimal implants and related methods |
US20090264861A1 (en) * | 2008-02-18 | 2009-10-22 | Qlt Plug Delivery, Inc. | Lacrimal implants and related methods |
US9132088B2 (en) | 2008-04-30 | 2015-09-15 | Mati Therapeutics Inc. | Composite lacrimal insert and related methods |
US9764066B2 (en) | 2008-04-30 | 2017-09-19 | Mati Therapeutics Inc. | Composite lacrimal insert and related methods |
US20110082214A1 (en) * | 2008-05-09 | 2011-04-07 | Gruenthal Gmbh | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
US9949942B2 (en) | 2008-05-09 | 2018-04-24 | Mati Therapeutics Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
US20090280158A1 (en) * | 2008-05-09 | 2009-11-12 | Qlt Plug Delivery, Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
US20100040672A1 (en) * | 2008-06-09 | 2010-02-18 | Northwestern University | Delivery of therapeutics |
US10799593B2 (en) | 2008-06-09 | 2020-10-13 | Northwestern University | Nanodiamond particle complexes |
EP2154241A2 (en) | 2008-08-12 | 2010-02-17 | The Regents of the University of Michigan | Cell culture well-plates having inverted colloidal crystal scaffolds |
US8409606B2 (en) | 2009-02-12 | 2013-04-02 | Incept, Llc | Drug delivery through hydrogel plugs |
US20100209478A1 (en) * | 2009-02-12 | 2010-08-19 | Sawhney Amarpreet S | Drug delivery through hydrogel plugs |
US8563027B2 (en) | 2009-02-12 | 2013-10-22 | Incept, Llc | Drug delivery through hydrogel plugs |
US20100274204A1 (en) * | 2009-02-23 | 2010-10-28 | Qlt Plug Delivery, Inc. | Lacrimal implants and related methods |
US10238535B2 (en) | 2009-02-23 | 2019-03-26 | Mati Therapeutics Inc. | Lacrimal implants and related methods |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US8434489B2 (en) | 2009-10-23 | 2013-05-07 | Conceptus, Inc. | Contraceptive devices and methods |
WO2011049694A1 (en) | 2009-10-23 | 2011-04-28 | Conceptus, Inc. | Contraceptive devices |
US20110094519A1 (en) * | 2009-10-23 | 2011-04-28 | Vidya Gopal | Contraceptive devices and methods |
US9421121B2 (en) | 2009-10-23 | 2016-08-23 | Bayer Healthcare Llc | Contraceptive devices and methods |
US10272164B2 (en) | 2009-12-15 | 2019-04-30 | Incept, Llc | Implants and biodegradable tissue markers |
EP3583960A1 (en) | 2009-12-15 | 2019-12-25 | Incept, LLC | Implants and biodegradable fiducial markers |
US11786612B2 (en) | 2009-12-15 | 2023-10-17 | Incept, Llc | Implant and biodegradable tissue marker compositions and methods |
US11160883B2 (en) | 2009-12-15 | 2021-11-02 | Incept, Llc | Echolucent implant composition and methods |
US11154624B2 (en) | 2009-12-15 | 2021-10-26 | Incept, Llc | Echolucent implant compositions and methods |
US9669117B2 (en) | 2009-12-15 | 2017-06-06 | Incept, Llc | Implants and biodegradable tissue markers |
EP3960215A1 (en) | 2009-12-15 | 2022-03-02 | Incept, LLC | Implants and biodegradable fiducial markers |
US20110142936A1 (en) * | 2009-12-15 | 2011-06-16 | Patrick Campbell | Implants and biodegradable fiducial markers |
US8852646B2 (en) | 2009-12-15 | 2014-10-07 | Incept, Llc | Particulate implants and biodegradable fiducial markers |
US11083802B2 (en) | 2009-12-15 | 2021-08-10 | Incept, Llc | Echolucent implant compositions and methods |
WO2011084465A2 (en) | 2009-12-15 | 2011-07-14 | Incept, Llc | Implants and biodegradable fiducial markers |
US10786581B2 (en) | 2009-12-15 | 2020-09-29 | Incept, Llc | Implants and biodegradable tissue markers |
US8383161B2 (en) | 2009-12-15 | 2013-02-26 | Incept, Llc | Radioopaque covalently crosslinked hydrogel particle implants |
US9308283B2 (en) | 2009-12-15 | 2016-04-12 | Incept, Llc | Implants and biodegradable fiducial markers |
US20110187017A1 (en) * | 2010-02-03 | 2011-08-04 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
US9579285B2 (en) | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
WO2011122524A1 (en) | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | Controlled release pharmaceutical composition |
WO2012025930A3 (en) * | 2010-08-25 | 2012-04-19 | Ocure Ltd. | Medical instruments of treating and/or diagnosing of anorectal disorders, and devices and methods for insertion of such |
US9566420B2 (en) | 2010-08-25 | 2017-02-14 | Ocure Ltd. | Medical instruments of treating and/or diagnosing of anorectal disorders, and devices and methods for insertion of such |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US9610271B2 (en) | 2011-08-29 | 2017-04-04 | Mati Therapeutics Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
US9974685B2 (en) | 2011-08-29 | 2018-05-22 | Mati Therapeutics | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
US10632012B2 (en) | 2011-08-29 | 2020-04-28 | Mati Therapeutics Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
EP3613413A1 (en) | 2011-12-05 | 2020-02-26 | Incept, LLC | Medical organogel processes and compositions |
WO2013086015A1 (en) | 2011-12-05 | 2013-06-13 | Incept, Llc | Medical organogel processes and compositions |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US11377498B2 (en) | 2014-10-24 | 2022-07-05 | Incept, Llc | Extra luminal scaffold |
US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
EP3858329A1 (en) | 2014-12-10 | 2021-08-04 | Incept, LLC | Hydrogel drug delivery implants |
WO2016094646A1 (en) | 2014-12-10 | 2016-06-16 | Incept, Llc | Hydrogel drug delivery implants |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US11369591B2 (en) | 2015-05-12 | 2022-06-28 | Incept, Llc | Drug delivery from hydrogels |
EP4279064A2 (en) | 2015-05-12 | 2023-11-22 | Incept, LLC | Drug delivery from hydrogels |
WO2016183296A1 (en) | 2015-05-12 | 2016-11-17 | Incept, Llc | Drug delivery from hydrogels |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US10420724B2 (en) | 2015-11-25 | 2019-09-24 | Incept, Llc | Shape changing drug delivery devices and methods |
US10786462B2 (en) | 2015-11-25 | 2020-09-29 | Incept, Llc | Shape changing drug delivery devices and methods |
US11413250B2 (en) | 2015-11-25 | 2022-08-16 | Incept, Llc | Shape changing drug delivery devices and methods |
US11938223B2 (en) | 2015-11-25 | 2024-03-26 | Incept, Llc | Shape changing drug delivery devices and methods |
WO2017091749A1 (en) | 2015-11-25 | 2017-06-01 | Incept, Llc | Shape changing drug delivery devices and methods |
EP4197527A1 (en) | 2016-09-23 | 2023-06-21 | Incept, LLC | Intracameral drug delivery depots |
WO2018058048A1 (en) | 2016-09-23 | 2018-03-29 | Incept, Llc | Intracameral drug delivery depots |
USD829390S1 (en) * | 2016-12-23 | 2018-09-25 | Jurox Pty Ltd | Intravaginal device |
WO2019161307A1 (en) | 2018-02-16 | 2019-08-22 | Esperion Therapeutics, Inc. | Sustained release formulations of bempedoic acid |
WO2021029429A1 (en) | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | Oral pharmaceutical composition |
WO2021029430A1 (en) | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | Oral pharmaceutical composition containing heterocyclic compound |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3865108A (en) | Expandable drug delivery device | |
JP4691734B2 (en) | Device for selectively supplying a drug to a target position on the wall of a patient's body cavity, blood vessel or the like | |
US3918443A (en) | Method for birth control | |
JPS6033958Y2 (en) | Hydration-inflatable ear canal insert for drug administration | |
US3428046A (en) | Catheter | |
US4304232A (en) | Unit system having multiplicity of means for dispensing useful agent | |
US3746003A (en) | Multi-lumen balloon catheter | |
CA1233716A (en) | Rectal insert | |
US3559646A (en) | Tampon | |
CN103418071B (en) | The expandable catheter of resist collapse | |
US2112160A (en) | Method of and apparatus for effecting medicinal treatment | |
US3736939A (en) | Balloon catheter with soluble tip | |
US4207893A (en) | Device using hydrophilic polymer for delivering drug to biological environment | |
US3779241A (en) | Intrauterine contraceptive device and method for its use | |
US4180073A (en) | Device for delivering drug to biological environment | |
US4071027A (en) | Method for flushing the uterus of a sow | |
JPS60237016A (en) | Drug dispenser | |
US4192308A (en) | Device using prestretched polymer for dispensing medication | |
US4223061A (en) | Hydrophilic laminate useful for making dispensing device | |
US3840010A (en) | Suppository | |
US2333342A (en) | Suppository | |
IL39454A (en) | Drug delivery device | |
JP2909477B2 (en) | Retrievable pessary | |
DE2622111A1 (en) | EXTENSION PROBE FOR THE EXPANSION OF BODY CAVES | |
CN215605602U (en) | Cervical dilator |